Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 20/20 | 1.00 |
| ▸ | NOS3 | P29474 | 18/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 10/20 | 1.00 |
| ▸ | NOS2 | P35228 | 8/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264616 | 0.93 | NOS3 (0.88) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL1122321 | 0.91 | NOS1 (1.00) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL2260909 | 0.84 | NOS3 (0.87) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL1121976 | 0.84 | NOS1 (1.00) | NOS1NOS3SLC6A2NOS2CYP3A4 | |
| SCHEMBL2262968 | 0.82 | NOS1 (0.72) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL4131599 | 0.81 | NOS3 (0.69) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL4134619 | 0.80 | NOS3 (1.00) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL4134303 | 0.80 | NOS3 (1.00) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL1122047 | 0.80 | NOS3 (1.00) | NOS1NOS3SLC6A2NOS2KCNH2 | |
| SCHEMBL1121963 | 0.79 | NOS1 (1.00) | NOS1NOS3SLC6A2NOS2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | SLC6A2, AANAT, NOS3 | NOS1 5/4885NOS3 3/4885SLC6A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.